Last reviewed · How we verify
Zevalin (IBRITUMOMAB TIUXETAN)
Zevalin works by binding to CD20 on B cells and delivering a radioactive dose that kills the cells.
Zevalin (Ibritumomab Tiuxetan) is a CD20-directed Radiotherapeutic Antibody developed by Spectrum Pharmaceuticals. It targets B-lymphocyte antigen CD20, a protein found on the surface of B cells, and delivers a radioactive dose to these cells. Zevalin is approved for the treatment of Follicular non-Hodgkin's lymphoma and was first approved by the FDA in 2002. The commercial status of Zevalin is owned by Spectrum Pharmaceuticals, and its patented status is unknown. Key safety considerations include radiation exposure and potential side effects such as infusion reactions and hematologic toxicity.
At a glance
| Generic name | IBRITUMOMAB TIUXETAN |
|---|---|
| Sponsor | Spectrum Pharms |
| Drug class | CD20-directed Radiotherapeutic Antibody |
| Target | B-lymphocyte antigen CD20 |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | discontinued |
| First approval | 2002 |
Mechanism of action
Imagine your body's immune system as a group of soldiers. B cells are like the scouts, searching for and identifying threats. Zevalin is like a guided missile that targets these B cells, delivering a dose of radiation that kills them, helping to treat conditions like non-Hodgkin's lymphoma.
Approved indications
- Follicular non-Hodgkin's lymphoma
Common side effects
- Meningitis tuberculous
- Progressive multifocal leukoencephalopathy
- Myelodysplastic syndrome
- Sepsis
- Thrombocytopenia
- Neutropenia
- Acute myeloid leukaemia
- Bone marrow failure
- Mucosal inflammation
- Stem cell transplant
- Pancytopenia
- Disease progression
Key clinical trials
- Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma (PHASE2)
- Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma (PHASE3)
- S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma (PHASE2)
- A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan (PHASE2)
- Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation (PHASE1,PHASE2)
- A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (PHASE3)
- Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine (PHASE2)
- Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Biologic Exclusivity |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zevalin CI brief — competitive landscape report
- Zevalin updates RSS · CI watch RSS
- Spectrum Pharms portfolio CI